Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TARIS Biomedical has started a Phase 1B study to investigate LiRIS in patients who are suffering from moderate-to-severe interstitial cystitis (IC).
Subscribe to our email newsletter
TARIS is a specialty pharmaceutical company engaged in developing a pipeline of new therapeutics designed to leverage common, minimally invasive urologic procedures to deliver and maintain drug directly to target tissues.
TARIS’ LiRIS is designed to continuously deliver lidocaine over an extended period directly to the bladder for decreasing symptoms linked with IC, such as bladder pain and voiding dysfunction.
TARIS president and CEO Sarma Duddu said the initiation of this Phase 1B clinical study builds upon a previously completed Phase 1A study in which they successfully established proof-of-concept by demonstrating the tolerability and retention of the TARIS delivery device in the bladder.